Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Stephen Mandel Remains Among Valeant Bulls; Betting Big on Tech in Q4

Page 1 of 2

Billionaire Stephen Mandel‘s Lone Pine Capital lost money in the third quarter, although three of its funds: Lone Cypress, Lone Kauri, and Lone Tamarack declined by 3.5%, 3.6%, and 3.7%, respectively, outperforming the S&P 500, which slid by 6.4%. On the other hand, its Lone Cascade dropped by 9.6%. Nevertheless, Mandel remained confident in his top picks and took their decline as an opportunity to boost Lone Pine’s exposure to some of these companies. In this article we are going to take a look at Lone Pine’s top five holdings as reported in its latest 13F filing.

Lone Pine Capital 2015 Q2 Investor Letter

Lone Pine held an equity portfolio worth $24.55 billion at the end of September, down from $26.73 billion a quarter earlier. The investor had around half of that invested in technology and healthcare stocks. The reason we analyze Lone Pine’s equity portfolio is because we believe that imitating some of its long picks can help a retail investor outperform the market. In fact, we analyze the equity portfolios of some 730 investors and by identifying stocks that they are collectively bullish on, we have managed to obtain returns of 102% since August 2012. Our approach outperformed the broader market by more than 53 percentage points by imitating the 15 most popular small-cap stocks among the funds we track (see more details here).

The 20% drop in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was viewed by many hedge fund managers as an opportunity to buy more shares with the conviction that the problems faced by the pharmaceutical giant are short-term. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s stock has lost another 50% since the end of the third quarter however, as more concerns about some of the company’s practices have arisen and short-sellers began targeting the vulnerable company. Nevertheless, Lone Pine acquired more than 2.15 million shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) between July and September, and reported ownership of 7.46 million shares valued at $1.33 billion in its latest 13F filing. Other shareholders of the company include billionaires Jeff Ubben of ValueAct Capital and Bill Ackman of Pershing Square.

Follow Valeant Pharmaceuticals International Inc. (NYSE:VRX)
Trade (NYSE:VRX) Now!

On the other hand, in Priceline Group Inc (NASDAQ:PCLN), Lone Pine inched down its stake by 16% to 992,252 shares worth $1.23 billion. Priceline Group Inc (NASDAQ:PCLN)’s shares have advanced by over 12% since the beginning of the year as the company has posted better-than-expected results for the last several quarters. Billionaire Leon Cooperman’s Omega Advisors is also bullish on Priceline Group Inc (NASDAQ:PCLN), holding 115,025 shares. Last month, Omega Advisors reiterated its bullish position and projected an 18% growth rate for the company’s stock over the next three-to-five years.

Follow Priceline Group Inc. (NASDAQ:PCLN)
Trade (NASDAQ:PCLN) Now!

Billionaire Stephen Mandel’s other top picks are represented by Charter Communications, Inc. (NASDAQ:CHTR), JD.Com Inc (ADR) (NASDAQ:JD), and Microsoft Corporation (NASDAQ:MSFTand we are going to discuss them on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!